How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes

Washington University School of Medicine54 enrolled

Overview

The purpose of this research study is to examine the relationship between the microbiota (microscopic organisms) in the gut and the activity of the immune system during skin cancer immunotherapy.

Details will be available upon publication.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Autoimmunity Melanoma Merkel Cell Carcinoma Squamous Cell Carcinoma of the Skin Basal Cell Carcinoma Skin Cancer

Interventions

ImmunotherapyBIOLOGICAL

Medications that increase the activity of the immune system.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * ≥18 years of age. * Diagnosis of skin cancer. * Planning to initiate or already on ANY type of immunotherapy. * Able to provide urine and stool specimens. Exclusion Criteria: * Bowel resection. * Major GI surgery in the past 5 years other than cholecystectomy and appendectomy.

Locations (1)

Barnes-Jewish Hosptial

St Louis, Missouri, United States

Outcomes

Primary Outcomes

Immune-related Adverse Events (irAEs)

Electronic medical records will be queried for specific drug-related adverse events known as immune-related Adverse Events (irAEs) including but not limited to colitis, hypophysitis, hepatitis, pneumonitis, pancreatitis, arthritis, rash, and vitiligo.

Time frame: 2 years

Secondary Outcomes

Overall Survival

Time frame: 2 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.